Male sexual dysfunction in obesity: The role of sex hormones and small fibre neuropathy

Jan Hoong Ho1,2, Safwaan Adam1,2, Shazli Azmi2, Maryam Ferdousi2, Yifen Liu2, Alise Kalteniece2, Shaishav S. Dhage1,2, Brian G. Keevil3, Akheel A. Syed4, Basil J. Ammori5, Tomás Ahern6, Rachelle Donn2, Rayaz A. Malik2,7, Handrean Soran1,2*

1 Department of Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2 Cardiovascular Research Group, The University of Manchester, Manchester, United Kingdom, 3 Department of Biochemistry, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 4 Department of Diabetes & Endocrinology, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 5 Department of Surgery, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 6 Department of Endocrinology, Our Lady of Lourdes Hospital, RCSI Hospital Group, Drogheda, Ireland, 7 Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar

* hsoran@aol.com, Handrean.Soran@mft.nhs.uk

Abstract

Context

Multiple factors contribute to sexual dysfunction in men with obesity. Sex hormone levels are commonly abnormal in men with obesity and this abnormality is often the focus of management in clinical practice. The role of small fibre neuropathy in obesity-related sexual dysfunction is not well established.

Objective

We aimed to investigate the relationship between sexual function, sex hormone levels and small nerve fibre morphology in men with severe obesity.

Materials and methods

A prospective study of 29 men with severe obesity was undertaken. Sexual function was assessed using the European Male Ageing Study Sexual Function Questionnaire. Small nerve fibre morphology was quantified using corneal confocal microscopy. Sex hormone levels were measured by mass spectrophotometry.

Results

Erectile dysfunction was present in 72% of the cohort with a higher prevalence of diabetes among the symptomatic group (88% vs 38%, p = 0.006). Corneal nerve fibre length (CNFL) and corneal nerve fibre density (CNFD) were both significantly lower in participants with erectile dysfunction compared to those without (p = 0.039 and p = 0.048 respectively). The erectile function score correlated with CNFL (r = -0.418, p = 0.034) and CNFD (r = -0.411, p = 0.037). Total testosterone and calculated free testosterone levels did not differ significantly between men with or without erectile dysfunction (median 8.8 nmol/L vs 9.0 nmol/L, p = 0.914; and median 176 pmol/L vs 179 pmol/L, p = 0.351 respectively), infrequent sexual
thoughts (median 8.1 nmol/L vs 9.2 nmol/L, p = 0.650; and median 184 pmol/L, vs 176 pmol/L, p = 0.619 respectively) and decreased morning erections (median 9.0 nmol/L vs 8.8 nmol/L, p = 0.655; and median 170 pmol/L vs 193 pmol/L, p = 0.278 respectively).

Conclusion

Sexual dysfunction is highly prevalent in men with severe obesity. We found an association between small fibre neuropathy with erectile dysfunction with presence of diabetes a likely a significant contributing factor. We found no associations between testosterone levels with sexual symptoms (including frequency of sexual thoughts). The influence of small nerve fibre neuropathy on response to therapeutic interventions and whether interventions that improve small fibre neuropathy can improve erectile function in this population merits further study.

Introduction

Sexual dysfunction is common in men with obesity [1]. Normal sexual functioning is dependent on complex vascular, neural, hormonal and psychological factors, all of which are potentially affected by obesity [2, 3]. Low testosterone level, in particular, is thought to have a bidirectional relationship with obesity [4, 5] and is common in men with obesity [6] and is very common in men with severe obesity [7, 8]. Current guidelines recommend testosterone replacement in men with symptomatic androgen deficiency to improve general well-being, bone mineral density and sexual function [9]. Whilst testosterone therapy may improve sexual symptoms in hypogonadal men [9], evidence that it benefits sexual function in men with obesity and low levels of testosterone is inconsistent [10–13].

Erectile dysfunction is associated with diminished small and large nerve fibre sensory thresholds [14]. Peripheral neuropathy, especially small fibre neuropathy, occurs more commonly in people with obesity than in those without [15, 16]. Corneal confocal microscopy is a rapid, validated and non-invasive technique that assesses small nerve fibre integrity [17, 18] with comparable diagnostic efficiency to intraepidermal nerve fibre density in diabetic peripheral neuropathy [19]. We have recently shown that small fiber neuropathy, quantified using corneal confocal microscopy, is associated with erectile dysfunction in men with type 1 diabetes [20].

We aimed to assess, for the first time, whether relationships exist between sexual symptoms with small fibre neuropathy and/or with sex hormone levels in men with severe obesity.

Materials and methods

Participants

Twenty-nine male patients with severe obesity were recruited from the weight management clinic at Salford Royal National Health Service Foundation Trust (Salford, United Kingdom). Severe obesity is defined as BMI above 40 which is equivalent to obesity class III using the BMI classification set out by the World Health Organisation (WHO) [21]. Patients known to have cardiovascular disease, disease of the pituitary, testes or adrenal glands, or taking therapy for erectile dysfunction or known to affect androgen levels or cause erectile dysfunction and luteinising hormone >9.4 U/L (primary hypogonadism), were excluded [22]. Further exclusion criteria included: other causes of peripheral neuropathy apart from diabetes; cancer, radiotherapy or chemotherapy; previous eye surgery and corneal disease. Presence of comorbidities
such as hypertension and type 2 diabetes were determined on medical history. A HbA1c measurement at baseline was used in addition to identify patients with undiagnosed type 2 diabetes (HbA1c ≥ 48 mmol/mol) and pre-diabetes (HbA1c 42–47 mmol/mol) [23]. This study has approval from the Greater Manchester Central Research and Ethics Committee. Written informed consent was obtained from all individuals prior to participation.

**Sexual function assessment**

Sexual function was assessed using the European Male Ageing Study Sexual Function Questionnaire [24]. Three sexual symptoms were used for assessment of sexual function: erectile function, frequency of sexual thoughts, and frequency of morning erections. Participants were divided into symptomatic and asymptomatic groups using previously established cut-offs based on validated scores for each individual question relating to the three sexual symptoms [25, 26].

**Neuropathy assessment**

Symptoms of peripheral neuropathy was assessed using the neuropathy symptom profile (NSP). Cold (CT) and warm (WT) perception thresholds were assessed on the dorsolateral aspect of the left foot (S1) using the TSA-II NeuroSensory Analyser (Medoc, Ramat-Yishai, Israel). Electrodagnostic studies were undertaken using a Dantec Keypoint system (Dantec Dynamics, Bristol, UK). Vibration perception threshold (VPT) was established using a Hotwell Neurothesiometer (Scientific Laboratory Supplies, Wilfred, Nottingham, UK). Deep breathing heart rate variability (DB-HRV) was established using an ANX 3.0 autonomic nervous system monitoring device (ANSAR Medical Technologies, Philadelphia, PA, USA).

**Corneal confocal microscopy**

Corneal nerve morphology was assessed using corneal confocal microscopy [17, 27]. Corneal confocal microscopy (Heidelberg Retinal Tomograph III Rostock Cornea Module; Heidelberg Engineering, Heidelberg, Germany) was performed using our established protocol [27]. Six non-overlapping images from the centre of the cornea were selected per patient (three per eye) [28]. Automated image analysis was performed using ACCMetrics software (The University of Manchester, United Kingdom). Corneal nerve fibre length (total length of nerves in mm per mm²), corneal nerve fibre density (CNFD) (number of major nerves per mm²) and corneal nerve branch density (CNBD) (number of nerve branches per mm²) were quantified [29].

**Laboratory measurements**

Venous blood samples were obtained between the hours of 0800 and 1100 after an overnight fast of at least 12 hours. Apart from glycosylated haemoglobin (HbA1c) which was measured using standard laboratory methods in the Department of Biochemistry, Manchester University NHS Foundation Trust on the day of collection, all other laboratory measurements were performed at the end of the study. Serum or plasma, isolated within 2 hours of collection, was stored at 4˚C or -20˚C until analysed. Each serum aliquot was stored for a maximum of two years and underwent one freeze-thaw cycle only. Serum total testosterone, dihydrotestosterone, dehydroepiandrosterone sulphate and androstenedione levels were determined using liquid chromatography–tandem mass spectrometry in a validated clinical laboratory [30, 31]. Sex hormone-binding globulin, luteinising hormone and follicle-stimulating hormone levels were measured electrochemiluminescence immunoassay (Roche Diagnostics) using Roche® automated analysers (E170 platform). Serum free testosterone levels were calculated using the mass action equation described by Vermeulen [32] and participant-specific total testosterone,
sex hormone-binding globulin and albumin levels. A participant was considered to have a low testosterone level if either; his total testosterone level was less than 8 nmol/L; or his total testosterone level was between 8 and 11 nmol/L and his calculated free testosterone level was less than 220 pmol/L [25].

**Statistical analyses**

All statistical analyses were performed using SPSS for Windows (Version 23.0, IBM SPSS Statistics, Armonk, NY). Continuous variables were compared between groups using the independent samples t-test or, in the case of non-parametrically distributed data, the Mann-Whitney U test. Normality of data distribution was assessed for all continuous variables using the Shapiro-Wilk test. The chi-squared test was used for analysis of categorical data. Correlations between variables were assessed using Spearman’s analyses. Results are expressed as mean with standard deviation (SD) for parametric data and as median with interquartile range (IQR) for non-parametric data. No attempt was made to adjust for missing data. The level of statistical significance was set at less than 0.05 for all analyses.

**Results**

Sixteen (55%) of the participants had erectile dysfunction of whom 34% had severe erectile dysfunction. Infrequent sexual thoughts and decreased morning erections were reported in 13 (45%) and 23 (79%) of the participants respectively. The median overall satisfaction score corresponded with moderate dissatisfaction.

The median total testosterone was 9.0 nmol/L, 95% confidence interval ranged between 7.4 nmol/L and 11.1 nmol/L. The total testosterone level was less than 8 nmol/L in 12 (41%) participants, between 8 and 11 nmol/L in ten (34%) participants, of whom 4 (14%) had a calculated free testosterone level below 220 pmol/L.

**Erectile dysfunction**

When participants were divided into symptomatic and asymptomatic groups based on their erectile function scores, age was higher and body mass index was lower in the symptomatic group (Table 1). The prevalence of type 2 diabetes mellitus and hypertension were higher in those with erectile dysfunction. The HbA1c, however, did not differ significantly between the groups. The prevalence of dysglycaemia (pre-diabetes and type 2 diabetes mellitus) also did not differ between symptomatic and asymptomatic groups.

Both CNFL and CNFD were lower in participants with erectile dysfunction compared to those without (Table 2 and Fig 1). Erectile function score correlated with both CNFL (Spearman’s r = -0.418, p = 0.034) and CNFD (Spearman’s r = -0.411, p = 0.037).

The level of total testosterone, free testosterone, sex hormone-binding globulin, dihydrotestosterone, dehydroepiandrosterone sulphate and androstenendione did not differ between participants with and without erectile dysfunction (Table 1 and Fig 1). There was no difference in the prevalence of low testosterone between these two groups. Total and free testosterone did not correlate with erectile function (Spearman’s r = -0.083, p = 0.667 and Spearman’s r = -0.255, p = 0.181 respectively).

There were no difference in lipid profile between the two groups.

**Infrequent sexual thoughts and decreased morning erections**

Clinical, corneal nerve or hormone parameters did not differ between those with and without infrequent sexual thoughts (S2 Table) or in those with and without decreased morning
erections (S3 Table). Total and free testosterone did not correlate with frequency of sexual thoughts (Spearman’s r = 0.236, p = 0.218 and Spearman’s r = 0.179, p = 0.352 respectively) or with frequency of morning erections (Spearman’s r = 0.079, p = 0.682 and Spearman’s r = 0.186, p = 0.333 respectively). The HbA1c and lipid profile did not differ between patients with and without infrequent sexual thoughts and patients with and without decreased morning erections (S2 and S3 Tables).

Low testosterone
There was no difference in sexual symptom frequency between men with and without a low testosterone level (S4 Table).

Discussion
This is the first study to assess sexual function, small fibre neuropathy, sex hormone levels and their relationships simultaneously in men with severe obesity. Male sexual dysfunction was

Table 1. Comparison of demographics, clinical characteristics, and sex hormone levels between asymptomatic and symptomatic patients divided based on erectile function.

| Clinical characteristics | Asymptomatic based on erectile function (n = 13) | Symptomatic based on erectile function (n = 16) | p-value |
|--------------------------|-----------------------------------------------|-----------------------------------------------|---------|
| Age, years               | 44.4 ±8.4                                      | 52.1 ±10.9                                    | 0.045   |
| BMI, kg/m²               | 54.8 ±12.4                                     | 46.9 ±7.3                                     | 0.041   |
| Type 2 diabetes, n (%)   | 5 (38%)                                        | 14 (88%)                                      | 0.006   |
| Duration of diabetes, years | 5±3                     | 6±5                                             | 0.787   |
| Pre-diabetes and type 2 diabetes, n (%) | 10 (77%)                                         | 14 (88%)                                      | 0.453   |
| Hypertension, n (%)      | 4 (30%)                                        | 11 (68%)                                      | 0.042   |
| Antihypertensives, n     | 0 (0–1)                                        | 1 (0–2)                                       | 0.092   |
| Biochemistry             |                                               |                                               |         |
| HbA1c, mmol/mol          | 52±13                                          | 55±15                                          | 0.591   |
| Total cholesterol, mmol/l | 3.8±1.2                                        | 4.0±1.0                                       | 0.796   |
| Triglyceride, mmol/l     | 1.0±0.5                                        | 1.3±0.5                                       | 0.206   |
| HDL-C, mmol/l            | 1.01±0.38                                      | 0.95±0.22                                     | 0.702   |
| LDL-C, mmol/l            | 2.5±1.0                                        | 2.4±0.8                                       | 0.808   |
| Sex hormones             |                                               |                                               |         |
| Low testosterone, n (%)  | 7 (54)                                         | 10 (63)                                       | 0.638   |
| Total testosterone, nmol/L | 9.0 (6.4–12.3)                                 | 8.8 (6.4–11.0)                                | 0.914   |
| Free testosterone, pmol/L | 179 (132–311)                                  | 176 (120–216)                                 | 0.351   |
| Sex hormone-binding globulin, nmol/L | 29.2 (21.7–35.5)                         | 32.1 (21.7–38.3)                              | 0.559   |
| Luteinising hormone, mIU/Ml  | 2.3±1.2                                          | 3.5±1.9                                       | 0.059   |
| Follicle-stimulating hormone, mIU/L  | 4.2 (2.9–4.7)                                   | 3.5 (2.4–4.9)                                 | 0.779   |
| Dihydrotestosterone, nmol/L | 0.60 (0.34–0.98)                           | 0.62 (0.50–0.99)                              | 0.914   |
| Dehydroepiandrosterone sulphate, nmol/L | 2.2 (1.1–3.4)                               | 1.3 (0.9–3.6)                                 | 0.537   |
| Androstenedione, nmol/L   | 2.3 (1.6–3.0)                                   | 1.6 (1.3–2.4)                                 | 0.170   |

Notes: Data are presented as mean and standard deviation for normally-distributed variables and median and interquartile range for non-parametric variables. Independent t-test was performed for normally-distributed variables, Mann-Whitney U test for non-parametric variables, and chi-squared test for categorical variables when comparing asymptomatic and symptomatic groups. p < 0.05 is considered statistically significant.

Abbreviations: BMI, body mass index; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

https://doi.org/10.1371/journal.pone.0221992.t001
highly prevalent in our study population with symptomatic erectile dysfunction and reduction in frequency of sexual thoughts being present in 55% and 45% of patients, respectively. The vast majority of patients had overall sexual function scores below the mean value found in the European Male Ageing Study, despite being ten years younger (mean age of 49 compared to

Table 2. Comparison of measures of neuropathy between asymptomatic and symptomatic patients divided based on erectile function.

| Measure                        | Asymptomatic based on erectile function (n = 13) | Symptomatic based on erectile function (n = 16) | p-value |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|---------|
| NSP, /38                      | 0 (0–5)                                       | 4 (0–15)                                      | 0.131   |
| VPT, V                        | 13.3±5.6                                      | 16.3±7.2                                      | 0.296   |
| CT, °C                        | 22.6±5.9                                      | 20.6±8.2                                      | 0.528   |
| WT, °C                        | 41.0±2.3                                      | 41.9±3.3                                      | 0.437   |
| CNFL, mm/mm²                  | 20.29±3.21                                    | 16.74±4.45                                    | 0.039   |
| CNFD, no./mm²                 | 30.21 (27.34–33.59)                           | 27.60 (22.50–29.17)                           | 0.048   |
| CNBD, no./mm²                 | 60.75±33.53                                   | 45.70±24.86                                   | 0.201   |
| DB-HRV, beats/min             | 35 (24–44)                                    | 14 (12–23)                                    | 0.016   |

Notes: Data are presented as mean and standard deviation for normally-distributed variables and median and interquartile range for non-parametric variables. Independent t-test was performed for normally-distributed variables, Mann-Whitney U test for non-parametric variables, and chi-squared test for categorical variables when comparing asymptomatic and symptomatic groups. *p* < 0.05 is considered statistically significant.

Abbreviations: CNFD, corneal nerve fibre density; CNBD, corneal nerve branch density; CNFL, corneal nerve fibre length; CT, cold perception threshold; DB-HRV, deep breathing heart rate variability; NSP, neuropathy symptom profile; VPT, vibration perception threshold; WT, warm perception threshold.

https://doi.org/10.1371/journal.pone.0221992.t002

Fig 1. Comparison of corneal nerve parameters in asymptomatic and symptomatic patients based on erectile function score (a & b) and comparison of total and free testosterone levels between asymptomatic and symptomatic patients based on erectile function (c & d), frequency of sexual thoughts (e & f), and frequency of morning erections (g & h). CNFL and CNFD are both significantly lower in symptomatic compared to asymptomatic patients with erectile dysfunction (a & b). Data are presented as mean and standard deviation for normally-distributed variables and median and interquartile range for non-parametric variables. Erectile function questionnaire response categories: 1: always able to keep erection good enough for sexual intercourse, 2: usually able, 3: sometimes able, 4: never able. Abbreviations: CNFD, corneal nerve fibre density; CNFL, corneal nerve fibre length. *p*<0.05 is considered statistically significant.

https://doi.org/10.1371/journal.pone.0221992.g001
59 years) [24]. The level of distress related to sexual functioning was also higher compared to that observed in the European Male Ageing Study cohort.

We have demonstrated, for the first-time, that reduction in small nerve fibre indices occur in patients with severe obesity and erectile dysfunction. In particular, corneal nerve fibre density and length were significantly lower in patients with symptomatic erectile dysfunction and they correlated with erectile function. There was, however, no difference between corneal nerve branch density and the severity of erectile dysfunction. We hypothesise that this could be a result of constant changes in this parameter secondary to nerve regeneration. There was also evidence of autonomic dysfunction in patients with erectile dysfunction. Older age, obesity and a higher prevalence of diabetes and hypertension in the cohort with erectile dysfunction are likely to be the major contributors of corneal nerve loss in accord with our previous studies [33, 34] and our recent study in type 1 diabetes.

Although somatic and autonomic neuropathy are associated with erectile dysfunction [35], patients continue to have assessment of sex hormones and cardiovascular risk factors, but not neuropathy. Our study emphasizes the importance of assessing small fibre neuropathy as it plays an important role in the neurovascular regulation of erectile function [36, 37]. Although phosphodiesterase type 5 inhibitors (PDE5i) are used in the management of erectile dysfunction, they are less effective in people with nerve damage [38, 39]. Based on our study findings, we therefore suggest that assessment of small fibre neuropathy prior to initiation of PDE5i may help identify patients who are more likely to respond to treatment and corneal confocal microscopy provides a rapid, objective and clinically feasible method to assess small fibre damage and repair [17–19]. Larger studies will be required to prove this further.

In keeping with previously published studies, we found a high prevalence of low testosterone levels in this cohort of men with severe obesity [8]. However, testosterone levels were not associated with sexual symptoms and sexual symptom frequency did not differ between those with low and normal testosterone levels. This perhaps suggests that low testosterone might not be a major determinant of presence of sexual symptoms in severe obesity.

The limitations of this study are the cross-sectional design which limits the inference of cause and effect between small fibre neuropathy and erectile dysfunction. A larger sample size would have allowed adjustment of confounding factors for small fibre damage in relation to erectile dysfunction. A single sample to determine sex hormone levels may also be seen as a limitation, however, several studies have confirmed that testosterone levels do not fluctuate significantly when measured serially in a timed sample over several months [40–42].

**Conclusion**

We conclude that erectile dysfunction is common among men with severe obesity and is associated with small fibre neuropathy, likely to be further driven by older age, diabetes and cardiovascular risk factors. Corneal confocal microscopy is a rapid, non-invasive technique to quantify of small nerve fibre degeneration and regeneration. Prospective studies are required to assess the impact of small fibre neuropathy on the effectiveness of therapies for erectile dysfunction and whether interventions that improve small fibre neuropathy can improve erectile dysfunction in men with severe obesity.

**Supporting information**

S1 Table. Questions regarding sexual symptoms within the EMAS sexual function questionnaire and definitions of asymptomatic and symptomatic response categories. The
definitions of asymptomatic and symptomatic response categories are based on validated published criteria [25, 26].

S2 Table. Comparison of sex hormone levels between asymptomatic and symptomatic patients divided based on frequency of sexual thoughts. Notes: Data are presented as mean and standard deviation for normally-distributed variables and median and interquartile range for non-parametric variables. Independent t-test was performed for normally-distributed variables, Mann-Whitney U test for non-parametric variables, and chi-squared test for categorical variables. p<0.05 is considered statistically significant. Abbreviations: CNFD, corneal nerve fibre density; CNBD, corneal nerve branch density; CNFL, corneal nerve fibre length.

S3 Table. Comparison of sex hormone levels between symptomatic and asymptomatic patients divided based on frequency of morning erections. Notes: Data are presented as mean and standard deviation for normally-distributed variables and median and interquartile range for non-parametric variables. Independent t-test was performed for normally-distributed variables, Mann-Whitney U test for non-parametric variables, and chi-squared test for categorical variables. p<0.05 is considered statistically significant. Abbreviations: CNFD, corneal nerve fibre density; CNBD, corneal nerve branch density; CNFL, corneal nerve fibre length.

S4 Table. Comparison of sexual symptoms between groups with low testosterone and normal testosterone. Data are presented as median and interquartile range for non-parametric variables. Mann-Whitney U test was performed for non-parametric variables. Questionnaire response categories: erectile function: 1: always able to keep erection good enough for sexual intercourse, 2: usually able, 3: sometimes able, 4: never able; frequency of sexual thoughts and morning erection frequency: 1: none or once in the past month, 2: 2–3 times/month and 1 time/week, 3: 2–6 times/week, 4: ≥1/day; overall satisfaction: 0: very dissatisfied, 1: moderately dissatisfied, 2: equally satisfied and dissatisfied, 3: moderately satisfied, 4: very satisfied. Overall sexual function score ranges from 0 to 33 with higher scores corresponding with higher level of sexual functioning. Sexual functioning-related distress ranges from 0 to 20, with higher scores corresponding with higher level of distress. p<0.05 is considered statistically significant.

Acknowledgments

This work was supported by the National Institute for Health Research/Wellcome Trust Clinical Research Facility at Manchester University NHS Foundation Trust, Greater Manchester Clinical Research Network and research donation from AMGEN.

Author Contributions

Conceptualization: Jan Hoong Ho, Safwaan Adam, Handrean Soran.
Data curation: Jan Hoong Ho, Safwaan Adam, Shazli Azmi, Akheel A. Syed, Basil J. Ammori.
Formal analysis: Jan Hoong Ho, Safwaan Adam.
Investigation: Jan Hoong Ho, Maryam Ferdousi, Yifen Liu, Alise Kalteniece, Brian G. Keevil.
Methodology: Jan Hoong Ho, Safwaan Adam, Handrean Soran.
References

1. Steffen KJ, King WC, White GE, Subak LL, Mitchell JE, Courcoulas AP, et al. Sexual functioning of men and women with severe obesity before bariatric surgery. Surg Obes Relat Dis. 2016. Epub Sep 16. https://doi.org/10.1016/j.soard.2016.09.022 PMID: 27986585

2. Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev. 2001; 22(3):342–88. Epub 2001/06/16. https://doi.org/10.1210/edrv.22.3.0430 PMID: 11399748.

3. Soran H, Wu FC. Endocrine causes of erectile dysfunction. Int J Androl. 2005; 28 Suppl 2:28–34. Epub 2005/10/21. https://doi.org/10.1111/j.1365-2605.2005.00596.x PMID: 16236061.

4. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011; 34(7):1669–75. Epub 2011/06/29. https://doi.org/10.2337/dc10-2339 PMID: 21709300.

5. Diaz-Arnolla M, Schwarzk M, Swerdloff RS, Wang C. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res. 2009; 21(2):89–98. Epub 2008/10/10. https://doi.org/10.1038/ijir.2008.42 PMID: 18843273.

6. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93(7):2737–45. Epub 2008/02/14. https://doi.org/10.1210/jc.2007-1972 PMID: 18270261.

7. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60(7):762–9. Epub 2006/07/19. https://doi.org/10.1111/j.1742-1241.2006.00992.x PMID: 16846397.

8. Hofstra J, Loves S, van Wageningen B, Ruimans-Koerts J, Jansen I, de Boer H. High prevalence of hypogonadotrophic hypogonadism in men referred for obesity treatment. Neth J Med. 2008; 66(3):103–9. Epub 2008/03/20. PMID: 18349465.

9. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536–59. Epub 2010/06/09. https://doi.org/10.1210/jc.2009-2354 PMID: 20525905.

10. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinichenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010; 7(7):2572–82. Epub 2010/06/08. https://doi.org/10.1111/j.1743-6109.2010.01859.x PMID: 20524974.

11. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011; 34(4):828–37. Epub 2011/03/10. https://doi.org/10.2337/dc10-1233 PMID: 21366088.

12. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014; 99(10):3821–8. Epub 2014/07/01. https://doi.org/10.1210/jc.2014-1872 PMID: 24978674.

13. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016; 374(7):611–24. Epub 2016/02/18. https://doi.org/10.1056/NEJMoa1506119 PMID: 26885521.

14. Bleustein CB, Arazzo JC, Eckholdt H, Melman A. The neuropathy of erectile dysfunction. Int J Impot Res. 2002; 14(6):433–9. Epub 2002/12/21. https://doi.org/10.1038/sj.ijir.3900907 PMID: 12494274.
Male sexual dysfunction in obesity

15. Miscio G, Guastamacchia G, Brunani A, Priano L, Baudo S, Mauro A. Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst. 2005; 10(4):354–8. Epub 2005/11/11. https://doi.org/10.1111/j.1085-9498.2005.00047.x PMID: 16279884.

16. Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, et al. Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond). 2007; 31(2):226–35. Epub 2006/06/14. https://doi.org/10.1038/sj.ijo.0803418 PMID: 16770330.

17. Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003; 46(5):683–8. Epub 2003/05/10. https://doi.org/10.1007/s00125-003-1086-8 PMID: 12739016.

18. Pritchard N, Edwards K, Russell AW, Perkins BA, Malik RA, Efron N. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. Diabetes Care. 2015; 38(4):671–5. Epub 2015/01/13. https://doi.org/10.2337/dc14-2114 PMID: 25753881.

19. Chen X, Graham J, Dabraham MA, Petropoulos IN, Petropoulos G, Marshall A, et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care. 2015; 38(6):1138–44. Epub 2015/03/22. https://doi.org/10.2337/dc14-2422 PMID: 25794515.

20. Azmi S, Ferdousi M, Alam U, Petropoulos IN, Petropoulos G, Marshall A, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia. 2017; 60(6):1094–101. Epub 2017/03/31. https://doi.org/10.1007/s00125-017-4245-z PMID: 28357503.

21. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:i–xii, 1–253. Epub 2001/03/10. PMID: 11234459.

22. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95(4):1810–8. Epub 2010/02/23. https://doi.org/10.1210/jc.2009-1796 PMID: 20173018.

23. (NICE) NIHaCE. NICE Public Health Guideline 38. Type 2 diabetes: prevention in people at high risk. 2012.

24. O’Connor DB, Corona G, Forti G, Tajar A, Lee DM, Finn JD, et al. Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study sexual function questionnaire. The journal of sexual medicine. 2008; 5(6):1374–85. Epub 2008/03/12. https://doi.org/10.1111/j.1743-6109.2008.00781.x PMID: 18331267.

25. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363(2):123–35. Epub 2010/06/18. https://doi.org/10.1056/NEJMoa0911101 PMID: 20554979.

26. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. Int J Impot Res. 2000; 12(4):197–204. Epub 2000/11/18. PMID: 11079360.

27. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. Journal of visualized experiments: JoVE. 2011;(47). Epub 2011/01/21. https://doi.org/10.3791/2194 PMID: 21246893.

28. Kalteniece A, Ferdousi M, Adam S, Schofield J, Azmi S, Petropoulos I, et al. Corneal confocal microscopy is a rapid reproducible opthalmic technique for quantifying corneal nerve abnormalities. PLoS One. 2017; 12(8):e0183040. Epub 2017/08/18. https://doi.org/10.1371/journal.pone.0183040 PMID: 28817609.

29. Tavakoli M, Quatrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010; 33(8):1792–7. Epub 2010/05/04. https://doi.org/10.2337/dc10-0253 PMID: 20435796.

30. Gallagher LM, Owen LJ, Keevil BG. Simultaneous determination of androstenedione and testosterone in human serum by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2007; 44(Pt 1):48–56. Epub 2007/02/02. https://doi.org/10.1258/00045630777959522 PMID: 17270092.

31. Owen LJ, Wu FC, Butler RM, Keevil BG. A direct assay for the routine measurement of testosterone, androstenedione, dihydrotestosterone and dehydroepiandrosterone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem. 2016; 53(Pt 5):580–7. Epub 2015/11/22. https://doi.org/10.1177/000456321621096 PMID: 26589631.

32. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84(10):3666–72. Epub 1999/10/16. https://doi.org/10.1210/jcem.84.10.6079 PMID: 10523012.

33. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Risk Factors Associated With Corneal Nerve Alteration in Type 1 Diabetes in the Absence of Neuropathy: A Longitudinal In Vivo
Corneal Confocal Microscopy Study. Cornea. 2016; 35(6):847–52. Epub 2016/02/05. https://doi.org/10.1097/ICO.0000000000000760 PMID: 26845318.

34. Dehghani C, Pritchard N, Edwards K, Vagenas D, Russell AW, Malik RA, et al. Morphometric stability of the corneal subbasal nerve plexus in healthy individuals: a 3-year longitudinal study using corneal confocal microscopy. Invest Ophthalmol Vis Sci. 2014; 55(5):3195–9. Epub 2014/04/26. https://doi.org/10.1167/iovs.14-13959 PMID: 24764058.

35. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care. 1996; 19(2):135–41. Epub 1996/02/01. PMID: 8718433.

36. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6(5):1232–47. Epub 2009/02/13. https://doi.org/10.1111/j.1743-6109.2008.01168.x PMID: 19210706.

37. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest. 1991; 88(1):112–8. Epub 1991/07/01. https://doi.org/10.1172/JCI115266 PMID: 1647413.

38. de Tejada IS. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res. 2004; 16 Suppl 1:S40–2. Epub 2004/06/30. https://doi.org/10.1038/sj.ijir.3901215 PMID: 15224136.

39. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009; 55(2):334–47. Epub 2008/11/07. https://doi.org/10.1016/j.eururo.2008.10.028 PMID: 18986755.

40. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010; 95(2):639–50. Epub 2010/01/12. https://doi.org/10.1210/jc.2009-1251 PMID: 20061435.

41. Keevil BG, MacDonald P, Macdowall W, Lee DM, Wu FC, Team N. Salivary testosterone measurement by liquid chromatography tandem mass spectrometry in adult males and females. Ann Clin Biochem. 2014; 51( Pt 3):368–78. https://doi.org/10.1177/0004563213506412 PMID: 24194586.

42. Vermueelen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992; 74(4):939–42. https://doi.org/10.1210/jcem.74.4.1548361 PMID: 1548361.